Here, we report the first study assessing the helper T lymphocyte precursor (HTLp) frequency as a predictor of outcome in patients undergoing allogeneic PBSC transplantation. The HTLp assay uses limiting dilution analysis to measure the frequency, in PBMCs from the donor, of T lymphocytes capable of producing IL-2 in response to histocompatibility antigenic differences on PBMCs from the recipient. This assay has shown promise as a functional histocompatibility assessment used to predict the risk of recipients of HLA-matched donor bone marrow developing severe acute GVHD: the higher the HTLp frequency, the greater the significance of any histoincompatibility, and the greater the risk of severe acute GVHD. In the current report, the HTLp frequency was measured in 28 HLA-identical sibling pairs who subsequently underwent allogeneic PBSC transplantation for haematological malignancies. The HTLp frequency did not predict for acute GVHD (P ‫؍‬ 0.38), chronic GVHD (P ‫؍‬ 0.95), transplant-related mortality (P ‫؍‬ 0.79), relapse (P ‫؍‬ 0.39) or overall survival (P ‫؍‬ 0.84). Converting the HTLp frequency to HTLp infused per kilogram of recipient body weight also did not predict for any of the outcome measures. We conclude that, although the HTLp assay may be useful for patients undergoing BMT, it does not predict for outcome after HLA-identical sibling donor G-CSFmobilised PBSC transplantation.
which may be due to cryptic HLA, not detectable by the methods used, or to minor histocompatibility antigens (mHA). On the other hand, some recipients of haematopoietic stem cells with a known HLA mismatch do not develop any GVHD ie, the antigenic mismatch is permissive. Hence, assays are needed that can detect the presence of significant cryptic HLA or mHA, and that can assess the functional significance of any known HLA or mHA differences between the recipient and any particular donor. Over the years, several functional assays such as the MLR, 2 the mixed lymphocyte-epidermal cell reaction, 3 the skinexplant assay, 4 ,5 the cytotoxic T lymphocyte precursor (CTLp) assay [5] [6] [7] [8] [9] [10] [11] and the helper T lymphocyte precursor (HTLp) assay 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] have been assessed by a number of investigators with mixed results.
The HTLp assay is a sensitive limiting dilution analysis that measures the frequency of T lymphocytes in the PBMC fraction of the donor's peripheral blood that produces IL-2 upon stimulation with PBMCs from the recipient. The HTLp frequency has been shown to predict for the incidence and severity of acute GVHD occurring in recipients of HLA-identical sibling donor bone marrow stem cells, [12] [13] [14] [15] [16] [17] and recipients of unrelated donor bone marrow stem cells. 7, 9, 14, 15 Although some investigators have found no such relationship after HLA-identical sibling donor bone marrow transplantation 5, 8, 11 or unrelated donor bone marrow transplantation. 10 The HTLp assay has not been assessed, to date, in donor/recipient pairs undergoing allogeneic peripheral blood stem cell transplantation. PBSCs, mobilised with G-CSF, are now frequently used as the source of haematopoietic stem cells for allogeneic transplantation. PBSC transplantation results in a more rapid engraftment but may increase the risk of acute and, particularly, chronic GVHD, 18, 19 perhaps because of the one log greater number of T lymphocytes infused with PBSCs as compared to bone marrow stem cells, although the incidence and severity particularly of acute GVHD appears to be somewhat less than expected with the greater number of T cells infused. 20 There is evidence to suggest that the G-CSF used to mobilise the PBSCs changes the character of the infused T cells -G-CSF skews helper T cells towards a type 2 (Th2) phenotype and the production of IL-4 and IL-10 rather than the type 1 (Th1) cytokines such as IL-2, IFN-␥ and TNF-␤.
21,22
Bone Marrow Transplantation Th2 cells appear to be less likely to induce clinically significant acute GVHD compared to Th1 cells. 22, 23 Our study is the first to assess whether or not the HTLp assay can predict outcome after allogeneic HLA-identical sibling donor transplantation using G-CSF-mobilised PBSC.
Materials and methods

Patients
Between January 1996 and December 1999, 28 patients and their HLA-identical sibling donors, who subsequently underwent PBSC transplantation, had peripheral blood taken for the HTLp assay. The donor PBMCs were obtained prior to G-CSF mobilisation. The patient demographics are listed in Table 1 . Standard disease included CML in chronic phase, non-transformed myelofibrosis, AML or ALL in CR1, or non-transformed low-grade NHL. Advanced disease included CML >CP1, AML/ALL with primary induction failure or >CR1, intermediate-grade NHL >CR1, Fanconi's anaemia with malignant transformation and multiple myeloma. Patients with advanced disease mostly received CsA alone as GVHD prophylaxis whereas patients with standard disease mostly received CsA and MTX. HLA identity was confirmed using standard serological techniques for class I and molecular techniques (SSOP) for class II. HLA-DP compatibility was not assessed.
Donors were mobilised with G-CSF (lenograstim; AMRAD Pharmaceuticals, Granville, NSW, Australia) at 25 
Samples
Heparinised peripheral blood from patient and donor were collected prior to G-CSF mobilisation and transplantation. The PBMCs were collected by density-gradient centrifugation, washed and cryopreserved until needed. Plasma was heat-inactivated, filtered and stored at −70°C until required.
Indicator cell line
The murine IL-2-dependent cell line, CTLL-2 (ATCC, Rockville, MD, USA) was maintained in RPMI-1640 (ICN, Seven Hills, NSW, Australia) supplemented with 10% foetal bovine serum (CSL, Melbourne, Victoria, Australia), 2% sodium pyruvate (Sigma-Aldrich Pty Ltd, Castle Hill, NSW, Australia) and 20 U/ml of IL-2 (Boehringer Mannheim Australia, Melbourne, Victoria, Australia). The CTLL-2 were passaged as required, usually every 3-4 days and replated with fresh medium and IL-2. Sixteen hours prior to use in the HTLp assay, the CTLL-2 were washed and maintained in medium without IL-2. A standard curve was included in every experiment to demonstrate the sensitive dose-dependent response of the IL-2 (0-2 U/ml) in the assay medium.
HTLp assay
The HTLp assay has been described in detail previously. 7 Briefly, the cryopreserved PBMC from patient (stimulator) and donor (responder) were thawed, washed and resuspended in assay medium (RPMI-1640 supplemented with 10% stimulator plasma). Irradiated (50 Gy) (Gammacell 1000, Nordion International Inc, Kanata, Ontario, Canada) recipient stimulator cells (10 5 cells per well in 100 l of medium) were cultured with graded numbers (1, 2, 4, 8, 10 ϫ 10 4 cells per well in 50 l of medium) of responder cells (24 replicates of each dilution) in round-bottomed 96-well microtitre plates (Linbro, ICN Biomedicals Australasia, Seven Hills, NSW, Australia). Negative controls were stimulator cells alone and responder cells alone. The positive controls consisted of two healthy HLA-mismatched samples tested against the responder and stimulator populations as well as each other. After 64 h, the plates were irradiated (20 Gy) and 5000 CTLL-2 in 25 l of medium were added to each well, incubated for 8 h at 37°C (95% air; 5% CO 2 ) and pulsed with 1 Ci per well of 3 Hthymidine (ICN Biomedicals Australasia). After a further 16 h incubation, the contents of the wells were harvested on to filter mats and the cpm were assessed on a liquid scintillation counter (Topcount, Canberra-Packard, Melbourne, Victoria, Australia).
Calculation of the HTLp frequency and the number of HTLp infused per kilogram of patient body weight
Microtitre wells were recorded as positive for IL-2 production if 3 H-thymidine incorporation was greater than the mean plus 3 standard deviations of the control wells. Minimal estimates of HTLp frequencies were obtained according to the Poisson distribution equation as the slope of the line relating the number of responder cells per well (plotted on the linear x-axis) and the fraction of wells that failed to produce detectable amounts of IL-2 (plotted on the logarithmic y-axis). The slope of the regression line was determined by using the maximum likelihood analysis method yielding: (1) a minimum frequency estimate; (2) the 95% confidence limits of this estimate; and (3) a chi-square estimate of probability (P) for the frequency estimate. In these studies, a P value of >0.05 indicates that the data conform to the zero-order term of the Poisson equation and that the frequency estimate is statistically acceptable. 26, 27 The number of HTLp infused per kilogram of patient body weight was calculated as follows: (HTLp frequency ϫ number of mononuclear cells infused) divided by the patient's body weight (kg).
Statistical analyses
The relationship between the HTLp frequency and acute GVHD, chronic GVHD, transplant-related mortality, relapse and overall survival, and the relationship between the HTLp number per kilogram of patient body weight infused and acute GVHD, chronic GVHD, transplantrelated mortality, relapse and overall survival were assessed by the Mann-Whitney test or the Kruskal-Wallis test (SYSTAT 8.0, SPSS, Chicago, IL, USA). Risk of relapse at HTLp frequencies > and Ͻ1 in 100 ϫ 10 3 were compared using the chi-square test.
Results
The HTLp assay was performed in the GVH direction on 28 HLA-identical sibling donor/recipient pairs ( Table 1) 
Acute GVHD
Twenty-seven patients were evaluable for acute GVHD. One patient died before engraftment and was not evaluable. The HTLp did not predict for the grade of acute GVHD (Kruskal-Wallis, P ϭ 0.38). There was no significant difference in HTLp frequencies between patients with nil to mild (grade 0 or A) acute GVHD compared to moderate to severe (grade B-D) acute GVHD (Mann-Whitney, P ϭ 0.86) (Table 2, Figure 1) , or between patients with nil to moderate (grade 0-B) acute GVHD compared to patients with moderately-severe to severe (grade C-D) acute GVHD (Mann-Whitney, P ϭ 0.98).
Bone Marrow Transplantation
The number of HTLp cells infused per kilogram of patient body weight was calculated (see Materials and methods). There was no association between the grades of acute GVHD and the HTLp frequencies infused per kilogram (Kruskal-Wallis, p=0.38). There was no significant difference in the number of HTLp per kilogram infused between patients with nil to mild (grade 0 or A) acute GVHD compared to moderate to severe grade (B-D) acute GVHD (Mann-Whitney, P ϭ 0.69), or patients with nil to moderate (grade 0-B) acute GVHD compared to patients with moderate severe to severe (grade C-D) acute GVHD (Mann-Whitney, P ϭ 0.45).
Chronic GVHD
Twenty-four of the 28 patients were evaluable for chronic GVHD. The HTLp did not predict for the severity of chronic GVHD (Kruskal-Wallis, P ϭ 0.95). There was no significant difference in HTLp frequencies between patients who developed no or limited chronic GVHD when compared to patients who developed extensive chronic GVHD (Mann-Whitney, P ϭ 0.95) (Table 2, Figure 2 ).
There was no significant difference in the number of HTLp per kilogram infused in patients with no or limited chronic GVHD compared with those who developed extensive chronic GVHD (Mann-Whitney, P ϭ 0.98).
Relapse
Eight patients had relapse of the original malignancy (Table  2 ). There was no statistical association between relapse and the HTLp frequency (Mann-Whitney, P ϭ 0.39) or relapse and the number of HTLp per kilogram infused (MannWhitney, P ϭ 0.96). There was no significant difference in the rate of relapse when comparing HTLp frequencies >1 in 100 ϫ 10 3 to HTLp frequencies <1 in 100 ϫ 10 3 (chisquare, P ϭ 0.61).
Outcome
Nine patients died from transplant-related complications. There was no association between the HTLp frequencies and transplant-related mortality (Mann-Whitney, P ϭ 0.95) or the number of HTLp cells infused per kilogram and transplant-related mortality (Mann-Whitney, P ϭ 0.79). The HTLp frequencies did not predict for survival (MannWhitney, P ϭ 0.84) nor did the number of HTLp infused per kilogram of patient body weight (Mann-Whitney, P ϭ 0.89).
Discussion
Histocompatibility matching of the donor and recipient prior to allogeneic stem cell transplantation is crucial to limit the incidence and severity of GVHD and to improve survival. Despite HLA identity, some recipients of HLAidentical sibling stem cells develop severe, lethal GVHD whereas some patients with known HLA mismatches develop no sign of GVHD. Hence, histocompatibility assays that have the ability to assess the functional significance of mHA mismatches, cryptic HLA mismatches and known HLA mismatches would be a useful addition to routine histocompatibility testing. A clinically useful functional histocompatibility assay could be used to assess the risk of a particular transplant recipient receiving haematopoietic stem cells from a particular donor. The MLR has been shown not to be useful as a functional assay prior to haematopoietic stem cell transplantation in recipients of HLA-identical sibling donor bone marrow 2 whereas other assays such as the mixed epidermal-lymphocyte cell reaction, 3 the skin explant assay, 4,5 the CTLp assay [5] [6] [7] [8] [9] [10] [11] and the HTLp assay 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] have shown promise. The HTLp assay, with some technical variations, has been assessed by several groups with conflicting results obtained. The HTLp frequency has been shown to predict for the incidence and severity of acute GVHD occurring in recipients of HLA-identical sibling donor bone marrow stem cells, [12] [13] [14] [15] [16] [17] and recipients of unrelated donor bone mar-row stem cells. 7, 9, 14, 15 However some investigators have found no such relationship after HLA-identical sibling donor bone marrow transplantation 5, 8, 11 or unrelated donor bone marrow transplantation. 10 To date, all functional assays, including the HTLp assay, have been assessed in donor/recipient pairs undergoing haematopoietic stem cell transplantation using bone marrow (without G-CSF mobilisation) as the source of the stem cells. However, the use of G-CSF-mobilised PBSCs as the source of haematopoietic stem cells is becoming more widely used. Our study is the first to investigate the relationship between HTLp frequency and outcome of recipients of HLA-identical sibling donor PBSC transplantation.
We measured the HTLp frequencies of 28 HLA-identical sibling donor/recipient pairs who subsequently underwent PBSC transplantation. We did not find any relationship between the pretransplant anti-recipient HTLp frequency and the incidence or severity of acute or chronic GVHD, the incidence of relapse, transplant-related mortality or overall survival.
Some authors have investigated whether or not the actual number of HTLp infused per kilogram of patient body weight rather than the HTLp frequency itself may be a better predictor of outcome. 9 We found no significant predictive ability of the number of HTLp infused per kilogram and the incidence and severity of acute GVHD, chronic GVHD or other outcome measures.
There are several possible explanations for the absence of a correlation between the HTLp frequency and GVHD after PBSC transplantation in our study. Perhaps the small number of donor/recipient pairs studied did not allow any correlation to be detected. Possibly the HTLp assay, in its current form, is not sensitive enough to reliably detect true HTLp frequencies, or perhaps the HTLp frequency, in any form, is simply not predictive of GVHD. An additional confounding factor may be that the post-transplant immunosuppression for the patient group was not uniform -25% received CsA alone whereas 75% received CsA and MTX.
A further possible explanation is that the pathophysiology of GVHD occurring after G-CSF-mobilised PBSC transplantation is altered compared to that occurring after BMT. It must be pointed out that although our patients received G-CSF-mobilised PBSCs the HTLp assays were performed using PBMCs collected prior to the G-CSF mobilisation, whereas all previous studies of HTLp frequencies have comprised patients receiving bone marrow that has not been subjected to G-CSF stimulation with the HTLp assays performed using PBMCs not exposed to G-CSF. Hence, the G-CSF may be a crucial factor.
Despite the infusion of one log more T lymphocytes with PBSC transplantation there appears to be only some increase in the incidence of acute GVHD, although probably a significant increase in the incidence of chronic GVHD compared to BMT. [18] [19] [20] There is evidence in mice 28, 29 and humans 22 suggesting that this may by due to a skewing of dendritic cells from type 1 to type 2, and a subsequent skewing from a helper T lymphocyte response type 1 (Th1), which produces IL-2, IFN-␥ and TNF-␤, towards the helper T lymphocyte response type 2 (Th2), which produces IL-4, IL-5, IL-6 and IL-10. Hence, the ILBone Marrow Transplantation 2-producing Th1 may not be as pivotal to the development of GVHD after G-CSF-mobilised PBSC transplantation. The HTLp assay detects IL-2 production only and therefore will not detect cytokine production by Th2. Therefore, it may be more clinically relevant to study the IL-2-producing HTLp frequencies of G-CSF mobilised PBMCs. In addition, the study of IL-4-producing HTLp frequencies may be of interest. 30 In summary, our study is the first to investigate the relationship between the HTLp frequency and outcome after allogeneic PBSC transplantation. The HTLp frequency did not predict for acute GVHD, chronic GVHD, relapse or survival in patients undergoing HLA-identical sibling donor G-CSF-mobilised PBSC transplantation.
